<DOC>
	<DOCNO>NCT02984579</DOCNO>
	<brief_summary>This multi-center , blind study determine performance YD Diagnostic Corporation ( YD ) REBA MTB-MDRÂ® Hain Genotype MTBDRplus V2 kit total 600 clinical isolates 900 residual sputum sample patient symptom pulmonary TB ( PTB ) risk drug resistance . All test do store , de-identified leftover sample . The study involve three World Health Organization ( WHO ) Supranational Reference Laboratories well-characterized strain collection access sputum sample significant rate drug resistance .</brief_summary>
	<brief_title>Line Probe Assay Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<criteria>Age 18 year Informed consent Patients evaluate pulmonary TB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>